The effects of combine treatment of memantine and donepezil on Alzheimer's Disease patients and its relationship with cerebral blood flow in the prefrontal area

International Journal of Geriatric Psychiatry

Volumn 29, Issue 9, 2014, Pages 881-889

  Araki, Tomoko ^a   Wake, Rei ^a   Miyaoka, Tsuyoshi ^a   Kawakami, Kazunori ^a   Nagahama, Michiharu ^a   Furuya, Motohide ^a   Limoa, Erlyn ^a   Liaury, Kristian ^a   Hashioka, Sadayuki ^a   Murotani, Kenta ^b   Horiguchi, Jun ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Alzheimer's Disease; donepezil; memantine; near infrared spectroscopy (NIRS); prefrontal area

Indexed keywords

ALANINE AMINOTRANSFERASE; DONEPEZIL; MEMANTINE; OXYHEMOGLOBIN; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; ASSOCIATION; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; CLOCK DRAWING TEST; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GAIT DISORDER; HUMAN; JAPANESE VERSION OF THE ZARIT BURDEN INTERVIEW; MAINTENANCE DRUG DOSE; MALE; MINI MENTAL STATE EXAMINATION; NEAR INFRARED SPECTROSCOPY; NEUROPSYCHIATRIC INVENTORY; PREFRONTAL CORTEX; SUPERIOR FRONTAL GYRUS; ANALYSIS OF VARIANCE; BRAIN CIRCULATION; BRIEF PSYCHIATRIC RATING SCALE; COST OF ILLNESS; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BRIEF PSYCHIATRIC RATING SCALE; CEREBROVASCULAR CIRCULATION; CHOLINESTERASE INHIBITORS; COGNITION; COST OF ILLNESS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDANS; MALE; MEMANTINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; PREFRONTAL CORTEX; SPECTROSCOPY, NEAR-INFRARED;

EID: 84905858594     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4074     Document Type: Article

References (19)

1. Arai Y, Kudo K, Hosokawa T, Washio M, Miura H, Hisamichi S,. 1997. Reliability and validity of the Japanese version of the Zarit Caregiver Burden interview. Psychiatry Clin Neurosci 51: 281-7. (Pubitemid 27463149)
2. Arai H, Takano M, Miyakawa K, et al,. 2006. A quantitative near-infrared spectroscopy study: a decrease in cerebral hemoglobin oxygenation in Alzheimer's disease and mild cognitive impairment. Brain Cogn 61: 189-94. (Pubitemid 43775978)
3. Asada T,. 1991. Analysis of breakdown in family care for patients with dementia. Psychiatr Neurol Jpn 93: 403-33.
4. Atri A, Molinuevo JL, Lemming O, et al,. 2013. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 5: 6.
5. Cummings JL, Schneider E, Tariot PN, Graham SM,. 2006. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 67: 57-63. (Pubitemid 44305462)
6. Farber NB, Rubin EH, Newcomer JW, et al,. 2000. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry 57: 1165-73.
7. Folstein MF, Folstein SE, McHugh PR,. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-98.
8. Freedman M, Leach L, Kaplan E, et al,. 1994. Clock Drawing: A Neuropsychological Analysis. Oxford University Press.
9. Hashimoto M., 2012. A report of cases that memantine treatment was remarkably effective for frontal lobe function and behavioral and psychological symptoms of dementia. Jpn J Geriatr Psychiatry 23: 1090-1095.
10. Herrmann MJ, Langer JBM, Jacob C, et al,. 2008. Reduced prefrontal oxygenation in Alzheimer disease during verbal fluency tasks. Am J Geriatr psychiatry 16: 125-35.
11. Jones RW,. 2010. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry 25: 547-553.
12. Royall DR, Cordes JA, Polk M,. 1998. CLOX: an executive clock drawing task. J Neurol Neurosurg Psychiatry 64: 588-94. (Pubitemid 28204143)
13. Schmidt R, Ropele S, Pendl B,. 2008. Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiatry 79: 1312-1317.
14. Schmitt FA, van Dyck CH, Wichems CH, Olin JT,. 2006. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord 20: 255-62. (Pubitemid 44900939)
15. Takizawa R, Kasai K, Kawakubo Y, et al,. 2008. Reduced frontopolar activation during verbal fluency task in schizophrenia: a multi-channel near-infrared spectroscopy study. Schizophr Res 99: 250-62.
16. Tariot PN, Farlow MR, Grossberg GT, et al,. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J Am Med Assoc 291: 317-24. (Pubitemid 38101604)
17. Tuokko H, Hadjistavropoulos T, Miller JA, Beattie BL,. 1992. The clock test: a sensitive measure to differentiate normal elderly from those with Alzheimer disease. J Am Geriatr Soc 40: 579-84.
18. Weiner MW, Sadowsky C, Saxton J, et al,. 2011. Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease. Alzheimers Dement 7: 425-435.
19. Zarit SH, Reever KE, Bach-Peterson J,. 1980. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 20: 649-55. (Pubitemid 11170845)